Serotonin and the Risk of Osseointegrated Implant Failure

03 September 2014

Selective Serotonin Reuptake Inhibitors and the Risk of Osseointegrated Implant Failure: A Cohort Study Selective serotonin reuptake inhibitors (SSRIs), the most widely used drugs for the treatment of depression, have been reported to reduce bone formation and increase the risk of bone fracture. Since osseointegration is influenced by bone metabolism, this study aimed to investigate the association between SSRIs and the risk of failures in osseointegrated implants. This retrospective cohort study was conducted on patients treated with dental implants from January 2007 to January 2013. A total of 916 dental implants in 490 patients (94 implants on 51 patients using SSRIs) were used to estimate the risk of failure

Within the limits of our study, we can conclude that SSRI treatment is associated with higher risk of osseointegrated implant failure. Implant survival rate could also be significantly influenced by other factors, such as implant diameter, bone augmentation, and smoking habits.
Author(s)	Source
Wu X, Al-Abedalla A, Rastikerdar E et al.	Journal of Dental Research, 03 Sep 2014, https://doi.org/10.1177/0022034514549378
This is a post of a scientific or business information. The information given here is checked thoroughly by “Implant-Register”. However we can´t be responsible for the content. Contact the publisher, if you have questions. You may inform us about changes of the information to improve the Register.
Comments: n/a let us know